Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series.

Given the mounting evidence for involvement of delta opioid receptors in the tolerance and physical dependence of mu opioid receptor agonists, we have investigated the possible physical interaction between mu and delta opioid receptors by using bivalent ligands. Based on reports of suppression of antinociceptive tolerance by the delta antagonist naltrindole (NTI), bivalent ligands [mu-delta agonist-antagonist (MDAN) series] that contain different length spacers, and pharmacophores derived from NTI and the mu agonist oxymorphone, have been synthesized and evaluated by intracerebroventricular (i.c.v.) administration in the tail-flick test in mice. In acute i.c.v. studies, the bivalent ligands functioned as agonists with potencies ranging from 1.6- to 45-fold greater than morphine. In contrast, the monovalent mu agonist analogues were substantially more potent than the MDAN congeners and were essentially equipotent with one another and oxymorphone. Pretreatment with NTI decreased the ED(50) values for MDAN-19 to a greater degree than for MDAN-16 but had no effect on MDAN-21. Chronic i.c.v. studies revealed that MDAN ligands whose spacer was 16 atoms or longer produced less dependence than either morphine or mu monovalent control MA-19. On the other hand, both physical dependence and tolerance were suppressed at MDAN spacer lengths of 19 atoms or greater. These data suggest that physical interaction between the mu and delta opioid receptors modulates mu-mediated tolerance and dependence. Because MDAN-21 was found to be 50-fold more potent than morphine by the i.v. route (i.v.), it offers a previously uncharacterized approach for the development of analgesics devoid of tolerance and dependence.

[1]  P. Portoghese,et al.  Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. , 1991, The Journal of pharmacology and experimental therapeutics.

[2]  Jamie Fong,et al.  A heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimers. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[3]  R. Schulz,et al.  Opiate receptor binding studies in the mouse vas deferens exhibiting tolerance without dependence , 1982, Naunyn-Schmiedeberg's Archives of Pharmacology.

[4]  H. Loh,et al.  Simultaneous quantitative assessment of morphine tolerance and physical dependence. , 1969, The Journal of pharmacology and experimental therapeutics.

[5]  D. Taylor,et al.  Unifying perspectives of the mechanisms underlying the development of tolerance and physical dependence to opioids. , 2001, The Journal of pharmacology and experimental therapeutics.

[6]  D. L. Larson,et al.  Opioid agonist and antagonist bivalent ligands. The relationship between spacer length and selectivity at multiple opioid receptors. , 1986, Journal of medicinal chemistry.

[7]  A. Takemori,et al.  Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence. , 1979, The Journal of pharmacology and experimental therapeutics.

[8]  D. L. Larson,et al.  Hybrid bivalent ligands with opiate and enkephalin pharmacophores. , 1987, Journal of medicinal chemistry.

[9]  W. Bowen,et al.  Lack of involvement of delta-1 opioid receptors in the development of physical dependence on morphine in mice. , 1994, The Journal of pharmacology and experimental therapeutics.

[10]  P. Munson,et al.  Dimeric pentapeptide enkephalin: a novel probe of delta opiate receptors. , 1982, Life sciences.

[11]  David J. Daniels,et al.  Interaction of Bivalent Ligand KDN21 with Heterodimeric δ-κ Opioid Receptors in Human Embryonic Kidney 293 Cells , 2005, Molecular Pharmacology.

[12]  R. Rothman,et al.  Mu and delta receptors: their role in analgesia in the differential effects of opioid peptides on analgesia. , 1982, Life sciences.

[13]  T. Coderre,et al.  Attenuation of morphine tolerance and dependence with the highly selective δ-opioid receptor antagonist TIPP[ψ] , 1995 .

[14]  Lakshmi A. Devi,et al.  A role for heterodimerization of μ and δ opiate receptors in enhancing morphine analgesia , 2004 .

[15]  D. L. Larson,et al.  Stereostructure-activity relationship of opioid agonist and antagonist bivalent ligands. Evidence for bridging between vicinal opioid receptors. , 1985, Journal of medicinal chemistry.

[16]  T. Haley,et al.  Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse. , 1957, British journal of pharmacology and chemotherapy.

[17]  P. Portoghese,et al.  From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes. , 2001, Journal of medicinal chemistry.

[18]  A. Kolinski,et al.  2-Ethyl and 2-ethylidene analogues of 1alpha,25-dihydroxy-19-norvitamin D(3): synthesis, conformational analysis, biological activities, and docking to the modeled rVDR ligand binding domain. , 2002, Journal of medicinal chemistry.

[19]  S K Saini,et al.  Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans. , 1999, Journal of medicinal chemistry.

[20]  Y. Imanishi,et al.  Binding to opioid receptors of enkephalin derivatives taking alpha-helical conformation and its dimer. , 2009, International journal of peptide and protein research.

[21]  Peter W. Schiller,et al.  The Opioid μ Agonist/δ Antagonist DIPP-NH2[Ψ] Produces a Potent Analgesic Effect, No Physical Dependence, and Less Tolerance than Morphine in Rats , 1999 .

[22]  Joshua F. Nitsche,et al.  Retention of Supraspinal Delta-like Analgesia and Loss of Morphine Tolerance in δ Opioid Receptor Knockout Mice , 1999, Neuron.

[23]  David J. Daniels,et al.  A Bivalent Ligand (KDN-21) Reveals Spinal δ and κ Opioid Receptors Are Organized as Heterodimers That Give Rise to δ1 and κ2 Phenotypes. Selective Targeting of δ−κ Heterodimers , 2004 .

[24]  Fred E. D'Amour,et al.  A METHOD FOR DETERMINING LOSS OF PAIN SENSATION , 1941 .

[25]  A. García-España,et al.  Antisense oligodeoxynucleotides to opioid mu and delta receptors reduced morphine dependence in mice: role of delta-2 opioid receptors. , 1997, The Journal of pharmacology and experimental therapeutics.

[26]  P. Portoghese,et al.  Design of peptidomimetic delta opioid receptor antagonists using the message-address concept. , 1990, Journal of medicinal chemistry.

[27]  D. Rodbard,et al.  Dimeric tetrapeptide enkephalins display extraordinary selectivity for the δ opiate receptor , 1982, Nature.

[28]  J. Levine,et al.  Different Mechanisms Mediate Development and Expression of Tolerance and Dependence for Peripheral μ-Opioid Antinociception in Rat , 1997, The Journal of Neuroscience.

[29]  B. O'dowd,et al.  Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. , 2000, The Journal of biological chemistry.

[30]  B. Kest,et al.  An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice , 1996, Brain Research Bulletin.

[31]  D. L. Larson,et al.  Opioid agonist and antagonist bivalent ligands as receptor probes. , 1982, Life sciences.

[32]  L. Devi,et al.  Dimerization of the delta opioid receptor: implication for a role in receptor internalization. , 1997, The Journal of biological chemistry.

[33]  O. Andreassen,et al.  Mice Deficient in Cellular Glutathione Peroxidase Show Increased Vulnerability to Malonate, 3-Nitropropionic Acid, and 1-Methyl-4-Phenyl-1,2,5,6-Tetrahydropyridine , 2000, The Journal of Neuroscience.

[34]  J. L. Wells,et al.  In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence. , 2001, The Journal of pharmacology and experimental therapeutics.

[35]  P. Portoghese,et al.  Narcotic antagonistic potency of bivalent ligands which contain .beta.-naltrexamine. Evidence for simultaneous occupation of proximal recognition sites , 1982 .

[36]  D. Rodbard,et al.  Receptor binding and biological activity of bivalent enkephalins. , 1985, Biochemical pharmacology.

[37]  P. Portoghese,et al.  Involvement of delta 2 opioid receptors in the development of morphine dependence in mice. , 1993, The Journal of pharmacology and experimental therapeutics.

[38]  P. Cuatrecasas,et al.  Increased biological activity of dimers of oxymorphone and enkephalin: possible role of receptor crosslinking. , 1982, Biochemical and biophysical research communications.

[39]  David J. Daniels,et al.  A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes. , 2004, Journal of medicinal chemistry.